{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:50Z","timestamp":1791252770073,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"International Myeloma Society - Bart Barlogie Young Investigator Award"},{"DOI":"10.13039\/501100004879","name":"Collegio Ghislieri di Pavia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ function. However, even complete hematologic response (CR), defined as negative serum and urine immunofixation and normalized free LC ratio, does not always translate into organ response. Next-generation flow (NGF) cytometry is used to detect minimal residual disease (MRD) in multiple myeloma. We evaluated MRD by NGF in 92 AL amyloidosis patients in CR. Fifty-four percent had persistent MRD (median 0.03% abnormal plasma cells). There were no differences in baseline clinical variables in patients with or without detectable MRD. Undetectable MRD was associated with higher rates of renal (90% vs 62%, <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and cardiac response (95% vs 75%, <jats:italic>p<\/jats:italic>\u2009=\u20090.023). Hematologic progression was more frequent in MRD positive (0 vs 25% at 1 year, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Altogether, NGF can detect MRD in approximately half the AL amyloidosis patients in CR, and persistent MRD can explain persistent organ dysfunction. Thus, this study supports testing MRD in CR patients, especially if not accompanied by organ response. In case MRD persists, further treatment could be considered, carefully balancing residual organ damage, patient frailty, and possible toxicity.<\/jats:p>","DOI":"10.1038\/s41408-021-00428-0","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T18:45:14Z","timestamp":1613587514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-0088","authenticated-orcid":false,"given":"Sriram","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Krsnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Basset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Nuvolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Lecumberri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Foli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania Antonietta","family":"Sesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Bozzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Cascino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Nevone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ripepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-2704","authenticated-orcid":false,"given":"Pierpaolo","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-7467","authenticated-orcid":false,"given":"Simona","family":"Casarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini, G. et al. Systemic immunoglobulin light chain amyloidosis. Nat. Rev. Dis. Primers 4, 38 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41375-020-0802-4","volume":"34","author":"OC Cohen","year":"2020","unstructured":"Cohen, O. C. & Wechalekar, A. D. Systemic amyloidosis: moving into the spotlight. Leukemia 34, 1215\u20131228 (2020).","journal-title":"Leukemia"},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41375-019-0619-1","volume":"34","author":"S Chattopadhyay","year":"2020","unstructured":"Chattopadhyay, S. et al. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia 34, 1187\u20131191 (2020).","journal-title":"Leukemia"},{"key":"428_CR4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","volume":"34","author":"S Sidana","year":"2020","unstructured":"Sidana, S. et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia 34, 1373\u20131382 (2020).","journal-title":"Leukemia"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","volume":"34","author":"E Muchtar","year":"2020","unstructured":"Muchtar, E. et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia 34, 1135\u20131143 (2020).","journal-title":"Leukemia"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/s41375-019-0664-9","volume":"34","author":"S Sidana","year":"2020","unstructured":"Sidana, S. et al. Revisiting complete response in light chain amyloidosis. Leukemia 34, 1472\u20131475 (2020).","journal-title":"Leukemia"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani, R. et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 134, 2271\u20132280 (2019).","journal-title":"Blood."},{"key":"428_CR8","first-page":"90","volume":"10","author":"P Milani","year":"2020","unstructured":"Milani, P. et al. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood. Cancer J. 10, 90 (2020).","journal-title":"Cancer J."},{"key":"428_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0306-5","volume":"10","author":"S Sidana","year":"2020","unstructured":"Sidana, S. et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 10, 41 (2020).","journal-title":"Blood Cancer J."},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","volume":"10","author":"S Sarosiek","year":"2020","unstructured":"Sarosiek, S. et al. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J 10, 88 (2020).","journal-title":"Blood Cancer J"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","volume":"131","author":"G Palladini","year":"2018","unstructured":"Palladini, G. et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood 131, 525\u2013532 (2018).","journal-title":"Blood"},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30, 4541\u20134549 (2012).","journal-title":"J. Clin. Oncol."},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini, G. et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124, 2325\u20132332 (2014).","journal-title":"Blood"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva, B., van Dongen, J. J. & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059\u20133068 (2015).","journal-title":"Blood"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"428_CR17","unstructured":"Paiva, B. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J. Clin. Oncol. 38, 784\u2013792 (2019)."},{"key":"428_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 133, 1953\u20131963 (2019).","journal-title":"Blood."},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2017.73.1331","volume":"35","author":"JL Harousseau","year":"2017","unstructured":"Harousseau, J. L. & Avet-Loiseau, H. Minimal residual disease negativity is a new end point of myeloma therapy. J Clin. Oncol. 35, 2863\u20132865 (2017).","journal-title":"J Clin. Oncol."},{"key":"428_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/21678707.2018.1549482","volume":"6","author":"P Milani","year":"2018","unstructured":"Milani, P., Merlini, G. & Palladini, G. What does minimal residual disease mean in AL amyloidosis? Expert Opin. Orphan Drugs. 6, 703\u2013705 (2018).","journal-title":"Expert Opin. Orphan Drugs."},{"key":"428_CR21","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/blood-2010-12-324665","volume":"117","author":"B Paiva","year":"2011","unstructured":"Paiva, B. et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood. 117, 3613\u20133616 (2011).","journal-title":"Blood."},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/cam4.725","volume":"5","author":"K Lisenko","year":"2016","unstructured":"Lisenko, K. et al. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Med. 5, 1464\u20131472 (2016).","journal-title":"Cancer Med."},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E. et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood 129, 82\u201387 (2017).","journal-title":"Blood"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","volume":"8","author":"E Kastritis","year":"2018","unstructured":"Kastritis, E. et al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J 8, 46 (2018).","journal-title":"Blood Cancer J"},{"key":"428_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.25746","volume":"95","author":"S Sidana","year":"2020","unstructured":"Sidana, S. et al. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Am. J. Hematol. 95, 497\u2013502 (2020).","journal-title":"Am. J. Hematol."},{"key":"428_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13506129.2019.1666709","volume":"27","author":"E Muchtar","year":"2020","unstructured":"Muchtar, E. et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid 27, 13\u201316 (2020).","journal-title":"Amyloid"},{"key":"428_CR27","doi-asserted-by":"crossref","unstructured":"Kastritis, E. et al. Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid 1\u20135 (2020).","DOI":"10.1080\/13506129.2020.1802713"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","volume":"4","author":"A Staron","year":"2020","unstructured":"Staron, A. et al. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 4, 880\u2013884 (2020).","journal-title":"Blood Adv."},{"key":"428_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"M Gertz","year":"2005","unstructured":"Gertz, M. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am. J. Hematol. 79, 319\u2013328 (2005).","journal-title":"Am. J. Hematol."},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","volume":"123","author":"L Diomede","year":"2014","unstructured":"Diomede, L. et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 123, 3543\u20133552 (2014).","journal-title":"Blood."},{"key":"428_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/ars.2016.6848","volume":"27","author":"L Diomede","year":"2017","unstructured":"Diomede, L. et al. Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage. Antioxid. Redox Signal. 27, 567\u2013582 (2017).","journal-title":"Antioxid. Redox Signal."},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini, G. et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107, 3854\u20133858 (2006).","journal-title":"Blood"},{"key":"428_CR33","doi-asserted-by":"crossref","unstructured":"Abeykoon, J. P. et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia 33, 531\u2013536 (2018).","DOI":"10.1038\/s41375-018-0262-2"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00428-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:40:08Z","timestamp":1669909208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00428-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P. reports honoraria for lectures from and membership on advisory boards with Jannsen-Cilag. B.P. reports honoraria for lectures from and membership on advisory boards with Amgen, Bristol-Myers Squibb, Celgene, Janssen-Cilag, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, and Sanofi; P.M. reports honoraria for lectures from Pfizer, Jannsen-Cilag, and travel support from Celgene; M.N. reports honoraria for lectures from Jannsen-Cilag; and R.L. received lecture fees from Jannsen-Cilag.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"34"}}